Molecular Subtyping of Breast Cancer-derived Small Extracellular Vesicles (sEVs) to Predict Therapeutic Efficacy
Molecular Subtyping of Breast Cancer-derived Small Extracellular Vesicles (sEVs) to Predict Therapeutic Efficacy: An Exploratory, Single-Center, Phase II Clinical Study
The goal of this observational study is to learn if a new diagnostic test using specific labels for breast cancer sEVs on a microchip can accurately diagnose the molecular subtypes in patients with breast cancer. The main questions it aims to answer are:
- What is the sensitivity of this new sEVs-based panel for diagnosing breast cancer molecular subtypes?
- What is the specificity of this new sEVs-based panel for diagnosing breast cancer molecular subtypes? Researchers will compare the results from the new sEVs panel to the results from the standard pathological diagnosis to see if the new panel is accurate and reliable.
Participants will be asked to:
- Provide blood samples and tissue samples.
- Allow researchers to access their clinical data, such as their diagnosis, treatment information, and outcomes.
研究概览
地位
条件
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Ting Li
研究联系人备份
- 姓名:Xiahong Wang
- 电话号码:8613524491606
- 邮箱:whx365@126.com
学习地点
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200032
- 招聘中
- Fudan University Shanghai Cancer Center
-
接触:
- Hongxia wang, PHD
- 电话号码:021-64175590
- 邮箱:whx365@126.com
-
接触:
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Age 18-75 years (inclusive)
- ECOG performance status 0-1
- Life expectancy ≥3 months
- Unresectable or metastatic breast cancer
- Core needle biopsy of recurrent/metastatic lesions is ongoing or planned before initiating new treatment regimen, with provision of fresh tumor tissue specimens and collection of peripheral blood samples
- Per RECIST v1.1 criteria, at least one measurable lesion or bone-only metastases
Adequate bone marrow reserve and organ function prior to first dose:
- Bone marrow reserve: Platelet count (PLT) ≥90 × 10⁹/L, absolute neutrophil count (ANC) ≥1.5 × 10⁹/L, hemoglobin ≥9 g/dL
- Coagulation function: INR ≤1.5, APTT ≤1.5 × ULN
- Hepatic function: Basically normal liver function, total bilirubin ≤1.5 × ULN (patients with Gilbert's syndrome may have total bilirubin ≤3 × ULN), AST and ALT ≤2.5 × ULN (if liver metastases are present, AST and ALT ≤5 × ULN)
- Renal function: Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/min (calculated by Cockcroft-Gault formula)
- Cardiac function: Left ventricular ejection fraction (LVEF) ≥50%; QTcF ≤470 ms for females, ≤450 ms for males Able to communicate effectively with the investigator and understand and comply with all requirements of the study -
Exclusion Criteria:
- Receipt of radiotherapy, chemotherapy, traditional Chinese medicine with anti-tumor indications, or local therapy (interventional treatment but excluding tumor biopsy, ablation therapy, etc.) within 2 weeks prior to enrollment
- Adverse reactions from previous anti-tumor treatment not recovered to ≤Grade 1 per CTCAE v5.0 (except for toxicities judged by the investigator to have no safety risk, such as alopecia, long-term toxicities from radiotherapy, or other toxicities ≤Grade 2)
- Other malignancies within the past 5 years, excluding cured cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin
- Uncontrolled or serious medical conditions, including but not limited to active infections requiring systemic antibiotic therapy
History of serious cardiovascular or cerebrovascular diseases, including but not limited to:
- Serious cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, second- to third-degree atrioventricular block, etc.
- Class III-IV cardiac dysfunction per New York Heart Association (NYHA) criteria
- Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other Grade ≥3 cardiovascular or cerebrovascular events within 6 months prior to first dose
- Clinically uncontrolled hypertension
- Any factors that increase the risk of QTc prolongation or arrhythmias, such as heart failure, hypokalemia, congenital long QT syndrome, or use of any concomitant medications known or suspected to prolong the QT interval
- History of immunodeficiency, including other acquired or congenital immunodeficiency diseases, or history of organ transplantation, allogeneic bone marrow transplantation, or autologous hematopoietic stem cell transplantation
HIV infection, active HBV or HCV infection; the following situations are allowed for enrollment:
- Patients positive for hepatitis B surface antigen (HBsAg), with or without positive hepatitis B core antibody (anti-HBc), if HBV DNA <500 IU/mL or below the lower limit of the study site's reference range, and active infection is ruled out by the investigator based on clinical treatment, presentation, etc.
- Patients positive for hepatitis C (HCV) antibody when HCV RNA is negative
- Females of childbearing potential with positive pregnancy test within 7 days prior to first dose or who are lactating
- Known psychiatric illness or disorder that may affect study compliance
- Other conditions judged by the investigator to be unsuitable for participation in this study
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
Phase 1(Model Building Cohort)
|
|
Phase 1(Model Building Cohort), Phase 2(External Validation Cohort)
Phase 1(Model Building Cohort): 500 participants will be enrolled to construct a classifier composed of sEVs molecules as a predictive model for molecular subtyping. Phase 2(External Validation Cohort): 1,000 participants will be enrolled to evaluate the sensitivity and specificity of sEVs-specific markers for breast cancer molecular subtyping diagnosis compared with classical pathological molecular subtyping diagnosis using ROC curves and other tools. This phase will delineate the distribution of sEVs molecular subtypes and explore the correlation between sEVs molecular subtypes and the efficacy of treatment regimens selected by physicians. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Sensitivity and specificity of sEVs-specific markers for breast cancer molecular subtyping diagnosis
大体时间:From baseline through treatment completion, up to 36 months
|
Sensitivity and specificity of sEVs-specific markers for breast cancer molecular subtyping diagnosis
|
From baseline through treatment completion, up to 36 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Distribution of sEVs molecular subtypes
大体时间:From baseline through treatment completion, up to 36 months
|
Distribution of sEVs molecular subtypes
|
From baseline through treatment completion, up to 36 months
|
|
Correlation analysis between sEVs molecular subtypes and drug efficacy
大体时间:From baseline through treatment completion, up to 36 months
|
Correlation analysis between sEVs molecular subtypes and drug efficacy
|
From baseline through treatment completion, up to 36 months
|
|
PFS (Progression-Free Survival)
大体时间:From treatment initiation until progression or death, up to 36 months
|
Time from start of treatment to the first documented disease progression per RECIST v1.1 or death due to any cause.
|
From treatment initiation until progression or death, up to 36 months
|
|
Overall Survival (OS) and Objective Response Rate (ORR)
大体时间:From treatment initiation until progression or death , up to 36 months
|
Objective Response Rate (ORR): As assessed according to the RESIST 1.1 criteria, with complete response (CR) and partial response (PR) combined to define a response. Overall Survival (OS): The time from enrolment to death from any cause; for lost-to-follow-up patients, survival is calculated as of the date of the last follow-up visit, and these are treated as censored data. |
From treatment initiation until progression or death , up to 36 months
|
|
Safety and Tolerability of Physician-Selected Treatment Regimens
大体时间:From treatment initiation until 30 days after the last dose, or until the initiation of a new antineoplastic therapy, whichever occurs first.
|
All subjects shall undergo toxicity assessment from the start of their first treatment, with toxicity assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.
|
From treatment initiation until 30 days after the last dose, or until the initiation of a new antineoplastic therapy, whichever occurs first.
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.